azd0914 and Urethritis

azd0914 has been researched along with Urethritis* in 2 studies

Other Studies

2 other study(ies) available for azd0914 and Urethritis

ArticleYear
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1

    We tested the activity of ETX0914 against 187 Neisseria gonorrhoeae isolates from men with urethritis in Nanjing, China, in 2013. The MIC50, MIC90, and MIC range for ETX0914 were 0.03 μg/ml, 0.06 μg/ml, and ≤0.002 to 0.125 μg/ml, respectively. All isolates were resistant to ciprofloxacin, and 36.9% (69/187) were resistant to azithromycin. Of the isolates, 46.5% were penicillinase-producing N. gonorrhoeae (PPNG), 36% were tetracycline-resistant N. gonorrhoeae (TRNG), and 13% (24 isolates) had an MIC of 0.125 μg/ml for ceftriaxone. ETX0914 may be an effective treatment option for gonorrhea.

    Topics: Anti-Bacterial Agents; Azithromycin; Barbiturates; Ceftriaxone; Ciprofloxacin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Gene Expression; Gonorrhea; Humans; Isoxazoles; Male; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; Tetracycline; Topoisomerase II Inhibitors; Urethritis

2016
In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.
    International journal of antimicrobial agents, 2016, Volume: 48, Issue:3

    Antimicrobial resistance in Neisseria gonorrhoeae has severely limited the number of treatment options, and the emergence of extended-spectrum cephalosporin resistance threatens the effectiveness of the last remaining recommended treatment regimen. This study assessed the in vitro susceptibility of N. gonorrhoeae to ETX0914, a novel spiropyrimidinetrione that inhibits DNA biosynthesis. In vitro activity was determined by agar dilution against 100 N. gonorrhoeae isolates collected from men presenting with urethritis in the USA during 2012-2013 through the Gonococcal Isolate Surveillance Project. The minimum inhibitory concentration (MIC) that inhibited growth in 50% (MIC50) and 90% (MIC90) of isolates was calculated for each antimicrobial agent. ETX0914 demonstrated a high level of antimicrobial activity against N. gonorrhoeae, including isolates with decreased susceptibility or resistance to currently available agents. The ability of ETX0914 to inhibit the growth of N. gonorrhoeae was similar to ceftriaxone, which is currently recommended in combination with azithromycin to treat gonorrhoea. The data presented in this study strongly suggest that ETX0914 should be evaluated in a clinical trial for the treatment of N. gonorrhoeae.

    Topics: Anti-Bacterial Agents; Barbiturates; Drug Resistance, Multiple, Bacterial; Gonorrhea; Humans; Isoxazoles; Male; Microbial Sensitivity Tests; Morpholines; Neisseria gonorrhoeae; Oxazolidinones; Spiro Compounds; United States; Urethritis

2016